Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) Operating Expenses (2024 - 2025)

Evommune (EVMN) has disclosed Operating Expenses for 2 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 38.51% to $29.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $77.7 million, a N/A change, with the full-year FY2025 number at $94.1 million, up 22.15% from a year prior.
  • Operating Expenses was $29.7 million for Q4 2025 at Evommune, up from $23.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $29.7 million in Q4 2025 to a low of $3.2 million in Q3 2024.